Literature DB >> 17587253

Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging.

M Cosottini1, R Ceravolo, L Faggioni, G Lazzarotti, M C Michelassi, U Bonuccelli, L Murri, C Bartolozzi.   

Abstract

OBJECTIVES: To assess midbrain atrophy through morphometric (linear, surface and volumetric) measurements in patients with clinically diagnosed progressive supranuclear palsy (PSP) and to establish the most accurate measure to be implemented in routine magnetic resonance (MR) protocol in distinguishing PSP from healthy subjects and MSA-p (multiple system atrophy, parkinsonian form) patients.
MATERIALS AND METHODS: We studied 15 patients with the diagnosis of probable PSP, seven patients with the diagnosis of probable MSA-p and 14 age-matched healthy volunteers. MR protocol includes a sagittal SE T1-weighted sequence for cross-sectional area and linear brainstem measurements and a 3D-FSPGR sequence for brainstem volume measurements.
RESULTS: A highly significant difference in the antero-posterior midbrain diameter, area and volume in PSP compared with control subjects was found. Only a measurement of the midbrain area and pons area enabled one to distinguish between PSP and MSA-p. Receiver operating characteristic analysis revealed that the midbrain area has the highest diagnostic accuracy in distinguishing between PSP and other conditions, with a sensitivity of 100% and specificity of 90.5%. The addition of the midbrain area/pons area ratio (A(ms)/A(pn) ratio) measurement improves the specificity in distinguishing between PSP and MSA.
CONCLUSIONS: Morphological indexes indicate midbrain atrophy in PSP patients The combination of the A(ms) and A(ms)/A(pn) ratio measurements allows to discriminate between PSP and other conditions.

Entities:  

Mesh:

Year:  2007        PMID: 17587253     DOI: 10.1111/j.1600-0404.2006.00767.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  28 in total

1.  In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS.

Authors:  Jitender Saini; Bhavani Shankara Bagepally; Mangalore Sandhya; Shaik Afsar Pasha; Ravi Yadav; Pramod Kumar Pal
Journal:  Neuroradiology       Date:  2011-12-09       Impact factor: 2.804

2.  Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials.

Authors:  Jennifer L Whitwell; Jia Xu; Jay N Mandrekar; Jeffrey L Gunter; Clifford R Jack; Keith A Josephs
Journal:  Parkinsonism Relat Disord       Date:  2011-11-13       Impact factor: 4.891

3.  Magnetic resonance imaging in progressive supranuclear palsy.

Authors:  M Stamelou; S Knake; W H Oertel; G U Höglinger
Journal:  J Neurol       Date:  2010-12-22       Impact factor: 4.849

4.  Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA.

Authors:  Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Val J Lowe; Clifford R Jack; Jennifer L Whitwell
Journal:  Neurology       Date:  2013-06-26       Impact factor: 9.910

5.  MRI Planimetry and Magnetic Resonance Parkinsonism Index in the Differential Diagnosis of Patients with Parkinsonism.

Authors:  V C Constantinides; G P Paraskevas; G Velonakis; P Toulas; E Stamboulis; E Kapaki
Journal:  AJNR Am J Neuroradiol       Date:  2018-04-05       Impact factor: 3.825

6.  MRI measurements of brainstem structures in patients with vascular parkinsonism, progressive supranuclear palsy, and Parkinson's disease.

Authors:  Byeong C Kim; Seong-Min Choi; Kang-Ho Choi; Tai-Seung Nam; Joon-Tae Kim; Seung-Han Lee; Man-Seok Park; Woong Yoon
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

7.  Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology.

Authors:  J L Whitwell; C R Jack; J E Parisi; J L Gunter; S D Weigand; B F Boeve; J E Ahlskog; R C Petersen; D W Dickson; K A Josephs
Journal:  Eur J Neurol       Date:  2013-06-07       Impact factor: 6.089

8.  Cerebral peduncle angle: Unreliable in differentiating progressive supranuclear palsy from other neurodegenerative diseases.

Authors:  Philip W Tipton; Takuya Konno; Daniel F Broderick; Dennis W Dickson; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2016-08-11       Impact factor: 4.891

9.  Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy.

Authors:  Salvatore Nigro; Gennarina Arabia; Angelo Antonini; Luca Weis; Andrea Marcante; Alessandro Tessitore; Mario Cirillo; Gioacchino Tedeschi; Stefano Zanigni; Giovanna Calandra-Buonaura; Caterina Tonon; Gianni Pezzoli; Roberto Cilia; Mario Zappia; Alessandra Nicoletti; Calogero Edoardo Cicero; Michele Tinazzi; Pierluigi Tocco; Nicolò Cardobi; Aldo Quattrone
Journal:  Eur Radiol       Date:  2016-10-19       Impact factor: 5.315

10.  Neuroimaging comparison of primary progressive apraxia of speech and progressive supranuclear palsy.

Authors:  J L Whitwell; J R Duffy; E A Strand; M M Machulda; M L Senjem; J L Gunter; K Kantarci; S D Eggers; C R Jack; K A Josephs
Journal:  Eur J Neurol       Date:  2012-10-18       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.